New radioactive injection targets Hard-to-Treat prostate cancer
NCT ID NCT07542379
First seen May 12, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early-stage study tests a new radioactive drug called 177Lu-FC516 in 13 men with advanced prostate cancer that no longer responds to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also look at whether the drug can shrink tumors or slow the cancer's growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.